Aislinn Antrim

Muvalaplin inhibits the formation of Lp(a) by blocking the initial interaction between apolipoprotein(a) [apo(a)] and apo(b). According to a news release, about 20% of individuals in the US have high levels of Lp(a), which can double or even triple the risk of heart attack as well as other cardiovascular issues.

This has been a concern with olanzapine monotherapy, limiting its clinical utility. Studies have noted that olanzapine alone can cause adverse cardiometabolic effects such as type 2 diabetes, dyslipidemia, and metabolic syndrome. The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain, with the newest data furthering this use.

In hospital and critical care settings, pharmacists can play a significant role in educating other health care providers about treatment options, proper dosing, and more.

Pharmacists play a critical role in ensuring the safe and effective use of ritonavir and nirmatrelvir. Their expertise in medication therapy management, drug-drug interactions, and patient counseling is invaluable in guiding patients through the treatment process. By identifying patients at high risk for progressing to severe disease and counseling them on their treatment options, pharmacists empower patients to make informed decisions about their treatment.

Although challenges and obstacles persist, artificial intelligence could help rural and smaller pharmacies close gaps in care.

Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.

The progress made in areas like scope expansion and reimbursement is encouraging, suggesting a growing recognition of pharmacists' value within the health care system. Similarly, the emerging shift toward a standard of care regulatory model holds significant promise for the future of pharmacy practice. By focusing on patient care outcomes and allowing qualified pharmacists to practice to the full extent of their training, this approach can improve access to care and enhance patient safety.

Results suggest that patients commonly receive more than 5 days of treatment, which could be an opportunity for an antimicrobial stewardship initiative.

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.